Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease Academic Article uri icon

Overview

MeSH Major

  • Aptamers, Nucleotide
  • Factor IXa
  • Oligonucleotides

abstract

  • This is the first experience of an RNA aptamer drug-antidote pair achieving inhibition and active restoration of factor IXa activity in combination with platelet-directed therapy in stable coronary artery disease. The preliminary clinical safety and predictable pharmacodynamic effects form the basis for ongoing studies in patients undergoing elective revascularization procedures.

publication date

  • June 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.107.745687

PubMed ID

  • 18506005

Additional Document Info

start page

  • 2865

end page

  • 74

volume

  • 117

number

  • 22